Target intelligence / Profile preview

Fungal β-1,3-glucan synthase

Molecular classification
Enzyme, Glycosyltransferase, Membrane protein complex
01

Overview

Fungal β-1,3-glucan synthase is a multisubunit enzyme complex located in the plasma membrane of fungal cells, essential for the biosynthesis of β-1,3-glucan, a major polysaccharide component of the fungal cell wall. The core catalytic subunit, known as Fks1 (and its homolog Fks2), utilizes UDP-glucose to elongate β-1,3-glucan chains that provide structural integrity to the fungal cell wall. Its activity is tightly regulated by small GTPases of the Rho family, essential for enzyme activation and cell wall homeostasis. Owing to the absence of β-1,3-glucan synthase in humans and its crucial role in fungal survival, this enzyme is an established, validated therapeutic target for antifungal drugs, mainly the echinocandin class (e.g., caspofungin, micafungin, anidulafungin) and the newer triterpenoid ibrexafungerp, both of which exert fungicidal or fungistatic effects by inhibiting cell wall glucan synthesis. Resistance can emerge due to mutations in FKS1 and FKS2, and the detection of β-1,3-glucan in bodily fluids serves as a biomarker for fungal infection and drug efficacy monitoring.

Other names
β-1,3-glucan synthase1,3-β-D-glucan synthaseFks1 (main catalytic subunit)Fks2 (paralog)GS
02

Mechanism of action

Inhibition of β-1,3-glucan synthase activity, leading to loss of cell wall integrity, cell wall stress, and fungal cell death. Noncompetitive inhibition (for some agents) of enzyme activity, resulting in cell wall disruption. Echinocandins and ibrexafungerp bind to the Fks1 subunit and inhibit glucan polymerization essential for cell wall biosynthesis.

03

Biological functions

Fungal cell wall biosynthesisβ-1,3-glucan synthesisCell wall structure maintenanceCell division (septum deposition)Ascospore wall assembly
04

Disease associations

Infection (target in fungal pathogens)
05

Safety considerations

Resistance mutations in FKS1 and FKS2 genes reduce drug efficacy (notable for echinocandins and other β-1,3-glucan synthase inhibitors).Effects limited to fungi owing to the absence of the enzyme in human cells, contributing to a favorable safety profile for targeting this enzyme.Some clinically relevant fungi (e.g., Cryptococcus) have intrinsic or acquired resistance.
06

Interacting drugs

Echinocandins (e.g., caspofungin, micafungin, anidulafungin)

3 more in the full profile.

07

Biomarkers

(1,3)-β-D-glucan in serum (for detection of invasive fungal infections as a biomarker of fungal burden/manipulation of pathway)

Beyond the preview

Go deeper on Fungal β-1,3-glucan synthase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fungal β-1,3-glucan synthase.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call